01—Abstract
Summary
Summary of the 10-K filed February 13, 2025. Cited figures are marked; the original filing is the authoritative source.
Zoetis Inc. reported strong financial performance for the fiscal year ended December 31, 2024, with total revenue reaching $9.26 billiona, an increase of 8% year-over-year.
This growth was driven by an 11%b operational revenue increase, fueled by price adjustments (6%) and volume growth from new products and key dermatology products (3% and 2% respectively). The company's U.S. segment showed robust growth of 11%, while the International segment experienced a 5% increase in revenue, partially impacted by unfavorable foreign exchange. Companion animal products continue to be the primary revenue driver, accounting for approximately 68% of total revenue, with livestock products making up 31%.
The company's top-selling products, Simparica/Simparica Trio and Apoquel/Apoquel Chewable, remain significant contributors to overall revenue. Zoetis demonstrated effective cost management, with cost of sales as a percentage of revenue decreasing to 29.4%c due to price increases, favorable product mix, and lower inventory and freight costs. Selling, general, and administrative expenses also saw an 8% increase, largely attributed to investments in compensation, selling, and promotional activities.
Research and development expenses grew by 12%, reflecting continued investment in innovation and portfolio progression. The company also completed the divestiture of its medicated feed additive product portfolio in October 2024, which will impact future revenue streams. Zoetis remains committed to returning value to shareholders, evidenced by its completed $3.5 billiond share repurchase program and a new $6 billion authorization, underscoring confidence in its future performance.
02—Key points
Key Highlights
- Total revenue increased by 8% to $9.26 billion in 2024, driven by an 11% operational revenue increase.
- Companion animal products represent 68% of revenue, with livestock products at 31%, showcasing a strong focus on pet health.
- Key products like Simparica/Simparica Trio and Apoquel/Apoquel Chewable continue to be major revenue drivers.
- The U.S. segment delivered strong revenue growth of 11%, while the International segment grew by 5%.
- Cost of sales as a percentage of revenue improved to 29.4% due to price increases and favorable product mix.
- R&D expenses increased by 12% to $686 million, highlighting continued investment in innovation.
- The company completed a $3.5 billion share repurchase program and announced a new $6 billion authorization, signaling strong capital return to shareholders.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-KFY2024filed February 13, 2025Financial Statements
FY2024 against FY2023
| Line item | FY2024FY2023 | Change |
|---|---|---|
| Revenue | $9.26B$8.54B | +8.3% |
| Cost of Revenue | $2.72B$2.56B | +6.2% |
| Gross Profit | $6.54B$5.98B | +9.3% |
| SG&A Expenses | $2.32B$2.15B | +7.8% |
| Interest Expense | $225.00M$239.00M | −5.9% |
| Net Income | $2.50B$2.34B | +6.7% |
| EPS (Basic) | $5.47$5.08 | +7.7% |
| EPS (Diluted) | $5.47$5.07 | +7.9% |
| Shares Outstanding (Basic) | 454.20M461.17M | −1.5% |
| Shares Outstanding (Diluted) | 454.85M462.27M | −1.6% |
05—Questions
Frequently Asked Questions
What was Zoetis's total revenue and revenue growth for the fiscal year ended December 31, 2024?
Zoetis reported total revenue of $9.26 billion for the fiscal year ended December 31, 2024, representing an 8% increase compared to the previous year. The operational revenue growth was 11%, driven by price increases and volume growth from new and key products.
How did Zoetis's business segments perform in 2024?
The U.S. segment experienced robust revenue growth of 11%, while the International segment saw a 5% increase in revenue. The international segment's growth was partially tempered by unfavorable foreign exchange movements.
What is the company's strategy regarding returning capital to shareholders?
Zoetis has demonstrated a strong commitment to shareholder returns. The company completed a $3.5 billion share repurchase program by the end of 2024 and has authorized a new share repurchase program of up to $6 billion. This indicates confidence in the company's financial health and its ability to generate cash for shareholder distributions.
What are the company's key product categories and top-selling products?
Zoetis's diversified product portfolio includes parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceuticals, and animal health diagnostics. Their top-selling products and product lines, such as Simparica/Simparica Trio and Apoquel/Apoquel Chewable, are significant contributors to revenue, with the top five product lines accounting for 41% of the company's revenue in 2024.
What impact did the divestiture of the medicated feed additive portfolio have?
Zoetis completed the divestiture of its medicated feed additive product portfolio, certain water soluble products, and related assets on October 31, 2024. While this divestiture will reduce future revenue from this specific category, the company is focused on its core animal health products and innovations.
06—Continue